WAYNE, Pa.,
Aug. 27, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP is
investigating potential claims against the board of directors of
Onyx Pharmaceuticals, Inc. ("Onyx" or the "Company") (NASDAQ: ONXX)
concerning possible breaches of fiduciary duty and other violations
of law related to the Company's efforts to sell the Company to
Amgen Inc. in a transaction valued at approximately
$10.4 billion.
(Logo:
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )
If you own shares of Onyx would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire
toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/onxx.
You may also email Mr. Maniskas at
rmaniskas@rmclasslaw.com.
Our investigation concerns possible breaches of fiduciary
duty and other violations of state law by the Board of Directors of
Onyx for not acting in the Company's shareholders' best interests
in connection with the sale process. Under the
terms of the agreement, shareholders of Onyx will receive
$125.00 per share in cash for each
share of Onyx they own.
Ryan & Maniskas, LLP is a national shareholder
litigation firm. Ryan & Maniskas, LLP is
devoted to protecting the interests of individual and institutional
investors in shareholder actions in state and federal courts
nationwide.
CONTACT:
Ryan &
Maniskas, LLP
Richard A. Maniskas,
Esquire
995 Old Eagle School Rd.,
Suite 311
Wayne,
PA
19087
877-316-3218
www.rmclasslaw.com/cases/onxx
rmaniskas@rmclasslaw.com
SOURCE Ryan & Maniskas, LLP